Lawmakers will negotiate during their October recess a long-term extension for a drug-development voucher program widely supported by drug companies but opposed by the FDA, industry observers told me.
President Barack Obama recently signed into law a three-month extension for a Food and Drug Administration program that encourages development of drugs that combat certain rare pediatric diseases, such as sickle cell disease, and pediatric cancers. The new law (S. 1878) gives lawmakers until Dec. 31 to agree on a long-term extension for the program, which could be key to its success.
The FDA's priority review vouchers reward companies that develop certain drugs with a voucher that can be used to speed agency approval of a future drug. The vouchers are valuable, in part, because they can be sold—one fetched $350 million—but pharmaceutical companies and their investors won't factor that value into their development costs for a new drug if they can't count on obtaining one because the program is set to expire.
“The voucher programs will be more effective at encouraging drug development if investors have greater certainty about receiving a voucher,” David Ridley, a professor at Duke University who first proposed the drug voucher programs, told me.
A long-term extension for the FDA's Rare Pediatric Disease Priority Review Voucher Program has been a priority for lobbyists working on behalf of the pharmaceutical industry throughout the most recent Congress, according to lobbying disclosure forms. More than a dozen pharmaceutical companies listed the bill on their lobbying disclosure forms in 2016.
Supporters of the program argue that there's often little incentive for pharmaceutical companies to invest in development of treatments for rare diseases because there's little return on investment for a drug that won't be widely used.
But, FDA officials told lawmakers they have no evidence the program is effective in encouraging the development of much-needed drugs to combat rare diseases and that the vouchers unfairly strain the agency's resources, an FDA spokeswoman told me.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)